monitoring cell to monitor the prices of non-scheduled bulk drugs/formulations.

(b) and (c) The required details are quite voluminous and are not readily available. The time and effort required for collection of these will not be commensurate with the results likely to be achieved.

(d) The cell monitors price changes of non-scheduled bulk drugs/formulations. Sales turnover is not monitored.

Marketing of dextropropoxyphene by M/s. Wockhardt

1563. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that dextropropoxyphene based formulations produced and marketed by Wockhardt are being marketed without any price approval;

(b) since when the process is going on and what is the present position; and

(c) what steps have been taken to calculate the amount overcharged and by when the company would be prosecuted and the excess amount recovered from it?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (c) To the extent information is available, M/s. Wockhardt have not applied for any price approval for formulations based on Dextropropoxyphene produced and marketed by them if any. The company has not submitted their price list in Form-5 under DPCO, 1987. The BICP has been requested to recommend the prices for such formulations sub-moto.

Settlement of formulation prices

1564. SHRI RAJNI RANJAN SAHU: Will the Minister of INDUSTRY be pleased to state:

(a) what are the names of non-scheduled bulk drugs and formulations for which the manufacturers have communicated their prices to his Ministry;

(b) what were their prices under DPCO 1979;

(c) what are the prices communicated by the manufacturers;

(d) whether it is a fact that his Ministry settled the prices for each of these bulk drug, and formulations;

(e) if so, what price was settled for each; and

(f) what is the procedure for settlement of price and what factors are being taken into consideration for such settlement?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) There are 27 bulk drugs and formulation in Schedule-I and 139 in Schedule-II. All other are price de-controlled. The required details in the question are quite voluminous and are not readily available. The time and effort required for collection of them will not be commensurate with the result likely to be achieved.

(f) As per the provisions of DPCO 1987, the manufacturers of non-scheduled bulk drugs/formulations are free to revise the prices. However, Government is keeping a watch and has intervened whrever found necessary.

Exhorbitant prices of certain drugs.

1565. PROF. C. LAKSHMANNA:
SHRI V. NARAYANASAMY:
SHRI RAM CHANDRA VIKAL:

Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that exhorbitant prices are being charged for Durabolin, Decadurabolin, Gestanon, Orabolin, Testoviron, Proluton-Dept and Dulcolax as the prices of these products have never been fixed in spite of monopolistic production;